Obesity treatment drug Mounjaro has been prescribed more than 1.5 million times in the 10 months since its domestic launch, reflecting surging demand for the weight-loss treatment. Concerns are growing about abuse among younger patients, as more than half of prescriptions were concentrated among people in their 20s and 30s, while prescriptions for teenagers rose 1.5 times this year alone. According to drug utilization review (DUR) data submitted by the Health Insurance Review and Assessment Service to Rep. Han Zee-a of the People Power Party on Wednesday, Mounjaro was prescribed 1,501,161 times between its domestic launch last August through May this year. Mounjaro, developed by U.S. pharmaceutical company Eli Lilly, is a once-weekly injectable that acts on GLP-1, a hormone that regulates appetite and blood sugar, to aid weight loss. Monthly prescriptions rose about 14.7 times, from 18,579 in August last year to 273,140 in May this year. By age group, people in their 30s accounted for the largest share at 36 percent, followed by those in their 40s at 27.1 percent, those in their 20s at 16